222 related articles for article (PubMed ID: 38382853)
21. Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study.
aus dem Siepen F; Buss SJ; Andre F; Seitz S; Giannitsis E; Steen H; Katus HA; Kristen AV
Clin Res Cardiol; 2015 Aug; 104(8):640-7. PubMed ID: 25855392
[TBL] [Abstract][Full Text] [Related]
22. Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles.
Knight DS; Zumbo G; Barcella W; Steeden JA; Muthurangu V; Martinez-Naharro A; Treibel TA; Abdel-Gadir A; Bulluck H; Kotecha T; Francis R; Rezk T; Quarta CC; Whelan CJ; Lachmann HJ; Wechalekar AD; Gillmore JD; Moon JC; Hawkins PN; Fontana M
JACC Cardiovasc Imaging; 2019 May; 12(5):823-833. PubMed ID: 29680336
[TBL] [Abstract][Full Text] [Related]
23. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis.
Karamitsos TD; Piechnik SK; Banypersad SM; Fontana M; Ntusi NB; Ferreira VM; Whelan CJ; Myerson SG; Robson MD; Hawkins PN; Neubauer S; Moon JC
JACC Cardiovasc Imaging; 2013 Apr; 6(4):488-97. PubMed ID: 23498672
[TBL] [Abstract][Full Text] [Related]
24. Cardiac MRI T1 and T2 Mapping as a Quantitative Imaging Biomarker in Transthyretin Amyloid Cardiomyopathy.
Yamaguchi S; Oda S; Kidoh M; Hayashi H; Takashio S; Usuku H; Nagayama Y; Nakaura T; Tsujita K; Hirai T; Aoki T
Acad Radiol; 2024 Feb; 31(2):514-522. PubMed ID: 37775448
[TBL] [Abstract][Full Text] [Related]
25. Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis.
Baggiano A; Boldrini M; Martinez-Naharro A; Kotecha T; Petrie A; Rezk T; Gritti M; Quarta C; Knight DS; Wechalekar AD; Lachmann HJ; Perlini S; Pontone G; Moon JC; Kellman P; Gillmore JD; Hawkins PN; Fontana M
JACC Cardiovasc Imaging; 2020 Jan; 13(1 Pt 1):69-80. PubMed ID: 31202744
[TBL] [Abstract][Full Text] [Related]
26. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study.
Banypersad SM; Sado DM; Flett AS; Gibbs SD; Pinney JH; Maestrini V; Cox AT; Fontana M; Whelan CJ; Wechalekar AD; Hawkins PN; Moon JC
Circ Cardiovasc Imaging; 2013 Jan; 6(1):34-9. PubMed ID: 23192846
[TBL] [Abstract][Full Text] [Related]
27. Comparing CMR Mapping Methods and Myocardial Patterns Toward Heart Failure Outcomes in Nonischemic Dilated Cardiomyopathy.
Vita T; Gräni C; Abbasi SA; Neilan TG; Rowin E; Kaneko K; Coelho-Filho O; Watanabe E; Mongeon FP; Farhad H; Rassi CH; Choi YL; Cheng K; Givertz MM; Blankstein R; Steigner M; Aghayev A; Jerosch-Herold M; Kwong RY
JACC Cardiovasc Imaging; 2019 Aug; 12(8 Pt 2):1659-1669. PubMed ID: 30448130
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Value of Myocardial Extracellular Volume Fraction and T2-mapping in Heart Transplant Patients.
Chaikriangkrai K; Abbasi MA; Sarnari R; Dolan R; Lee D; Anderson AS; Ghafourian K; Khan SS; Vorovich EE; Rich JD; Wilcox JE; Blaisdell JA; Yancy CW; Carr J; Markl M
JACC Cardiovasc Imaging; 2020 Jul; 13(7):1521-1530. PubMed ID: 32199848
[TBL] [Abstract][Full Text] [Related]
29. Diffuse Myocardial Fibrosis and Inflammation in Rheumatoid Arthritis: Insights From CMR T1 Mapping.
Ntusi NAB; Piechnik SK; Francis JM; Ferreira VM; Matthews PM; Robson MD; Wordsworth PB; Neubauer S; Karamitsos TD
JACC Cardiovasc Imaging; 2015 May; 8(5):526-536. PubMed ID: 25890584
[TBL] [Abstract][Full Text] [Related]
30. T
Maforo NG; Magrath P; Moulin K; Shao J; Kim GH; Prosper A; Renella P; Wu HH; Halnon N; Ennis DB
J Cardiovasc Magn Reson; 2020 Dec; 22(1):85. PubMed ID: 33302967
[TBL] [Abstract][Full Text] [Related]
31. Regional amyloid distribution and impact on mortality in light-chain amyloidosis: a T1 mapping cardiac magnetic resonance study.
Wan K; Li W; Sun J; Xu Y; Wang J; Liu H; Dong Y; Cheng W; Zhang Q; Zeng Z; Zhou X; Han Y; Chen Y
Amyloid; 2019 Mar; 26(1):45-51. PubMed ID: 30931628
[TBL] [Abstract][Full Text] [Related]
32. Reference Ranges, Diagnostic and Prognostic Utility of Native T1 Mapping and Extracellular Volume for Cardiac Amyloidosis: A Meta-Analysis.
Wang TKM; Brizneda MV; Kwon DH; Popovic ZB; Flamm SD; Hanna M; Griffin BP; Xu B
J Magn Reson Imaging; 2021 May; 53(5):1458-1468. PubMed ID: 33274809
[TBL] [Abstract][Full Text] [Related]
33. Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study.
Fontana M; Banypersad SM; Treibel TA; Abdel-Gadir A; Maestrini V; Lane T; Gilbertson JA; Hutt DF; Lachmann HJ; Whelan CJ; Wechalekar AD; Herrey AS; Gillmore JD; Hawkins PN; Moon JC
Radiology; 2015 Nov; 277(2):388-97. PubMed ID: 25997029
[TBL] [Abstract][Full Text] [Related]
34. Cardiac Involvement in Patients Recovered From COVID-2019 Identified Using Magnetic Resonance Imaging.
Huang L; Zhao P; Tang D; Zhu T; Han R; Zhan C; Liu W; Zeng H; Tao Q; Xia L
JACC Cardiovasc Imaging; 2020 Nov; 13(11):2330-2339. PubMed ID: 32763118
[TBL] [Abstract][Full Text] [Related]
35. Myocardial Edema and Prognosis in Amyloidosis.
Kotecha T; Martinez-Naharro A; Treibel TA; Francis R; Nordin S; Abdel-Gadir A; Knight DS; Zumbo G; Rosmini S; Maestrini V; Bulluck H; Rakhit RD; Wechalekar AD; Gilbertson J; Sheppard MN; Kellman P; Gillmore JD; Moon JC; Hawkins PN; Fontana M
J Am Coll Cardiol; 2018 Jun; 71(25):2919-2931. PubMed ID: 29929616
[TBL] [Abstract][Full Text] [Related]
36. Myocardial structural and functional changes in cardiac amyloidosis: insights from a prospective observational patient registry.
Duca F; Rettl R; Kronberger C; Binder C; Mann C; Dusik F; Schrutka L; Dalos D; Öztürk B; Dachs TM; Cherouny B; Camuz Ligios L; Agis H; Kain R; Koschutnik M; Donà C; Badr-Eslam R; Kastner J; Beitzke D; Loewe C; Nitsche C; Hengstenberg C; Kammerlander AA; Bonderman D
Eur Heart J Cardiovasc Imaging; 2023 Dec; 25(1):95-104. PubMed ID: 37549339
[TBL] [Abstract][Full Text] [Related]
37. Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy.
Rettl R; Mann C; Duca F; Dachs TM; Binder C; Ligios LC; Schrutka L; Dalos D; Koschutnik M; Donà C; Kammerlander A; Beitzke D; Loewe C; Charwat-Resl S; Hengstenberg C; Kastner J; Eslam RB; Bonderman D
Eur Heart J Cardiovasc Imaging; 2022 Jun; 23(6):767-780. PubMed ID: 34788394
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of left atrial function in systemic light-chain amyloidosis: a cardiac magnetic resonance study.
Mohty D; Boulogne C; Magne J; Varroud-Vial N; Martin S; Ettaif H; Fadel BM; Bridoux F; Aboyans V; Damy T; Jaccard A
Eur Heart J Cardiovasc Imaging; 2016 Sep; 17(9):961-9. PubMed ID: 27194782
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic value of cardiovascular magnetic resonance in comparison to endomyocardial biopsy in cardiac amyloidosis: a multi-centre study.
Chatzantonis G; Bietenbeck M; Elsanhoury A; Tschöpe C; Pieske B; Tauscher G; Vietheer J; Shomanova Z; Mahrholdt H; Rolf A; Kelle S; Yilmaz A
Clin Res Cardiol; 2021 Apr; 110(4):555-568. PubMed ID: 33170349
[TBL] [Abstract][Full Text] [Related]
40. [T1 mapping and late gadolinium enhancement for the diagnosis of dilated cardiomyopathy].
Cui Q; Yu J; Ge X; Gao G; Liu Y; Shen W
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Dec; 32(12):1506-1510. PubMed ID: 33541506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
